[11] The hypothesis underlying microdosing is that lower doses might provide some metabolic benefit whilst minimising these troublesome symptoms, potentially improving treatment adherence
It is crucial to emphasise that experiencing these signs does not confirm a GLP-1 issue, nor is "GLP-1 imbalance" a recognised clinical diagnosis
Convenient Size: 150ml bottle, perfect for daily use
In agreement, incubation of hepatocytes with saturated fatty acids decreased cell viability, while incubation with mono-unsaturated fatty acids enhanced lipid accumulation without affecting cellular viability [61]
However, Medicare may cover Wegovy when it is prescribed for cardiovascular risk reduction in eligible patients with obesity or overweight and known cardiovascular disease based on the SELECT trial indication
Dizziness: May cause sleepiness or light-headedness